Mycenax signs MoU with KriSan Biotech: Building ADC Industry Value Chain
After signing a Memorandum of Understanding (MoU) earlier this year with Industrial Technology Research Institute (ITRI), Mycenax Biotech Inc. (TWO: 4726) signed a Memorandum of Understanding (MoU) today with KriSan Biotech on Sept. 20th, 2022.
The MoU stipulates the strategic alliance between Mycenax and KriSan for providing CDMO services of ADCs (Antibody Drug Conjugates) for clients around the world.
The signing of the MoU comes within the framework of strengthening cooperation between Mycenax and KriSan in the field of ADCs, of which the manufacturing process includes the upstream ADC design and process development, midstream production of antibodies, linker, and payload, downstream ADC conjugation, purification, as well as the quality analysis and characterization of the ADC products.
In addition to the technical matters in the ADC production, the terms of the MoU also included the construction of an ADC dedicated GMP facility for ADC CDMO services.
Moreover, the two parties agreed on the features and implementation mechanisms of the agreement that Mycenax is responsible for the design, process development and scale-up of ADC, while KriSan is responsible for synthesis of small molecule drugs, the linkers and the payloads, and the GMP production of ADC.
About KriSan Biotech Co., Ltd.
Established in 2015, KriSan Biotech has more than ten years of professional experience in the API industry. KriSan is a pharmaceutical company with excellent R&D and manufactural capabilities providing services such as R&D, analytical method development and validation, cGMP API production, CMC writing and regulatory consultation, etc., and engaging in the development and manufacturing of high-tech barrier API, including small molecule organic synthesis, peptide synthesis, peptide drug, complexes, nucleic acid molecules, and complex drug molecules.
Company website: https://www.krisanbiotech.com/
About Mycenax
Mycenax Biotech Inc. (est. 2001) is the only biopharmaceutical CDMO company focusing on a one-stop service in Taiwan. The company's core value is to have the biological drug development technology and cGMP manufacturing plant in line with the regulatory requirements and market competitiveness and to bridge the research and development results with the commercialization of drugs. Mycenax is currently capitalized at 1.55 billion NTD.
Future Outlook
Mycenax has established its status as a “large development and medium manufacturing” CDMO company, with R&D investment to establish technical barriers, provide differentiated services, and through the strategic alliance to form a complete upper, middle and downstream value chain, providing a comprehensive one-stop service. Therefore, Mycenax actively promotes its novel technologies for developing emerging biological drugs, not only in ADC field, but also in the fields of allogeneic cell therapy, and exosomes
Mycenax signs MoU with KriSan Biotech: Building ADC Industry Value Chain
After signing a Memorandum of Understanding (MoU) earlier this year with Industrial Technology Research Institute (ITRI), Mycenax Biotech Inc. (TWO: 4726) signed a Memorandum of Understanding (MoU) today with KriSan Biotech on Sept. 20th, 2022.
The MoU stipulates the strategic alliance between Mycenax and KriSan for providing CDMO services of ADCs (Antibody Drug Conjugates) for clients around the world.
The signing of the MoU comes within the framework of strengthening cooperation between Mycenax and KriSan in the field of ADCs, of which the manufacturing process includes the upstream ADC design and process development, midstream production of antibodies, linker, and payload, downstream ADC conjugation, purification, as well as the quality analysis and characterization of the ADC products.
In addition to the technical matters in the ADC production, the terms of the MoU also included the construction of an ADC dedicated GMP facility for ADC CDMO services.
Moreover, the two parties agreed on the features and implementation mechanisms of the agreement that Mycenax is responsible for the design, process development and scale-up of ADC, while KriSan is responsible for synthesis of small molecule drugs, the linkers and the payloads, and the GMP production of ADC.
About KriSan Biotech Co., Ltd.
Established in 2015, KriSan Biotech has more than ten years of professional experience in the API industry. KriSan is a pharmaceutical company with excellent R&D and manufactural capabilities providing services such as R&D, analytical method development and validation, cGMP API production, CMC writing and regulatory consultation, etc., and engaging in the development and manufacturing of high-tech barrier API, including small molecule organic synthesis, peptide synthesis, peptide drug, complexes, nucleic acid molecules, and complex drug molecules.
Company website: https://www.krisanbiotech.com/
About Mycenax
Mycenax Biotech Inc. (est. 2001) is the only biopharmaceutical CDMO company focusing on a one-stop service in Taiwan. The company's core value is to have the biological drug development technology and cGMP manufacturing plant in line with the regulatory requirements and market competitiveness and to bridge the research and development results with the commercialization of drugs. Mycenax is currently capitalized at 1.55 billion NTD.
Future Outlook
Mycenax has established its status as a “large development and medium manufacturing” CDMO company, with R&D investment to establish technical barriers, provide differentiated services, and through the strategic alliance to form a complete upper, middle and downstream value chain, providing a comprehensive one-stop service. Therefore, Mycenax actively promotes its novel technologies for developing emerging biological drugs, not only in ADC field, but also in the fields of allogeneic cell therapy, and exosome